NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Swan Genomics

Swan Genomics

Private
SydneyHealthcare & Life Scienceshttps://www.swangenomics.com/

Last Round

Grant

Mar 5, 2026

Total Funding Raised

$5.77M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Swan Genomics is a biotechnology company that is developing a novel single-molecule DNA sequencing platform intended to make genomics data more accessible, scalable, and affordable.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Hardware + Subscription

AI Layer

Non-AI

Keywords

single-molecule sequencingDNA sequencing platformDNA sequencerthird-generation sequencinglong-read sequencinggene sequencingplasmonic nanoantennaebiotech equipmentnext-generation sequencingNGSpopulation genomicspersonalized medicinesequencing consumables

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Swan Genomics Comparables

Compare Swan Genomics with similar companies based on industry and business-model similarity.

Swan Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pacific Biosciences of California, Inc.
74%
Oxford Nanopore Technologies
72%
Element Biosciences
72%

Swan Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 5, 2026
GrantMar 10, 2025
Pre SeedSep 1, 2023

Key People

Founding team and executive leadership

Lawrence Lee

Founder And CEO

Founding Team

Swan Genomics Investors

Notable investors and investment history

Swan Genomics investors
InvestorRounds
InvestiblePre Seed
NSW GovernmentGrant
Proto AxiomPre Seed
In-Q-TelPre Seed
Pacific ChannelPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 5, 2026

    $320K raised from NSW Government

  • May 13, 2025

    Grew 30% QoQ from 10 to 13 employees.

Swan Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Swan Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Swan Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney
Employee Range11
Year Founded2023
Last FundingMar 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.